Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

This is a randomized double-blind pilot study to determine the clinical utility of using Oseltamirvir compared to placebo in the treatment of ITP. Oseltamivir is an attractive drug for ITP since it specifically targets a pathophysiologic mechanism that appears to be important for the development of ITP and has a benign side effect profile compared to standard ITP therapy. Eligibility includes adults with ITP who have not had a sustained response to other available treatments.


Status: Unknown

back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo